Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Bristol-Myers Squibb Company | Sitravatinib and OPDIVO (nivolumab) | Urothelial Carcinoma (Bladder) | Phase 2 | Trial Completed | Intravenous | Oncology |
| Bristol-Myers Squibb Company | Deucravacitinib - (IM011-127) | Ulcerative colitis (UC) | Phase 2 | Trial Discontinued | oral | Gastroenterology |
| Bristol-Myers Squibb Company | Opdualag (nivolumab and relatlimab-rmbw) - (RELATIVITY-047) | Melanoma | Phase 2/3 | Ongoing | Intravenous | Oncology |
| Bristol-Myers Squibb Company | BMS-986446 (PRX005) - (TargetTau-1) | Alzheimer’s disease | Phase 2 | Ongoing | Intravenous | Neurology |
| Bristol-Myers Squibb Company | Sitravatinib and Opdivo (Nivolumab) - (MRTX-500) | Nonsquamous (NSQ) Non–Small-Cell Lung Cancer (NSCLC) | Phase 2 | Trial Completed | Intravenous | Oncology |
| Bristol-Myers Squibb Company | Opdivo (anti-PD1) - (CheckMate-1533) | 1L Non-small Cell Lung Cancer (NSCLC) SC + IV | Phase 2 | Trial Planned | Intravenous | Oncology |
| Bristol-Myers Squibb Company | BMC128 with Opdivo | Non-small cell lung cancer (NSCLC), melanoma or renal cell carcinoma | Phase 2 | Trial Planned | Intravenous | Oncology |
| Bristol-Myers Squibb Company | nivolumab and relatlimab - (RELATIVITY-123) | Microsatellite stable (MSS) metastatic colorectal cancer (mCRC) | Phase 3 | Trial Discontinued | Intravenous | Oncology |
